Cargando…
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
BACKGROUND: The forced vital capacity (FVC) of healthy individuals depends on their age, sex, ethnicity and height. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterised by loss of FVC. We compared FVC values in the subjects with SSc-ILD in the SENSCIS trial of nintedani...
Autores principales: | Maher, Toby M., Bourdin, Arnaud, Volkmann, Elizabeth R., Vettori, Serena, Distler, Jörg H. W., Alves, Margarida, Stock, Christian, Distler, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258095/ https://www.ncbi.nlm.nih.gov/pubmed/35790961 http://dx.doi.org/10.1186/s12931-022-02095-6 |
Ejemplares similares
-
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial
por: Denton, Christopher P, et al.
Publicado: (2022) -
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020) -
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022) -
Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022) -
Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)